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During fibrosis the hepatic stellate cell (HSC) under-
goes a complex activation process characterized by in-
creased proliferation and extracellular matrix deposi-
tion. The 70-kDa ribosomal S6 kinase (p70S6K) is
activated by mitogens, growth factors, and hormones in
a phosphatidylinositol 3-kinase-dependent manner.
p70S6K regulates protein synthesis, proliferation, and
cell cycle control. Because these processes are involved
in HSC activation, we investigated the role of p70S6K in
HSC proliferation, cell cycle control, and type I collagen
expression. Platelet-derived growth factor (PDGF) stim-
ulated p70S6K phosphorylation, which was blocked by
LY294002, an inhibitor of phosphatidylinositol 3-kinase.
Rapamycin blocked phosphorylation of p70S6K but had
no affect on PDGF-induced Akt phosphorylation, posi-
tioning p70S6K downstream of Akt. Transforming
growth factor-, which inhibits HSC proliferation, did
not affect PDGF-induced p70S6K phosphorylation. Rapa-
mycin treatment did not affect 1(I) collagen mRNA but
reduced type I collagen protein secretion. Expression of
smooth muscle -actin was not affected by rapamycin
treatment, indicating that HSC activation was not al-
tered. Rapamycin inhibited serum-induced DNA synthe-
sis 2-fold. Moreover, rapamycin decreased expression
of cyclins D1, D3, and E but not cyclin D2, Rb-Ser780, and
Rb-Ser795. Together, p70S6K plays a crucial role in HSC
proliferation, collagen expression, and cell cycle con-
trol, thus representing a potential therapeutic target for
liver fibrosis.
Hepatic fibrosis is a pathologic response of the liver to acute
and chronic insults such as ethanol, viral infection, cholestasis,
and metabolic diseases (1). Hepatic stellate cells (HSCs)1 play
a crucial role in liver fibrosis, as they are responsible for ex-
cessive deposition of extracellular matrix proteins, of which
type I collagen predominates (2). After a fibrogenic stimulus,
HSCs transform from a quiescent vitamin A storing cell to an
activated myofibroblast-like cell (2). Morphological changes as-
sociated with HSC activation include a loss of vitamin A stores
and appearance of the cytoskeletal protein smooth muscle -ac-
tin (-SMA) (3, 4). Two major events occur after HSC activation
that substantially contribute to their active role in liver fibro-
sis. First, they are the primary cell type responsible for in-
creased synthesis and deposition of extracellular matrix pro-
teins in the liver (5). Second, activated HSCs proliferate
thereby effectively increasing the population of fibrogenic cells
and amplifying the fibrotic response (6).
The most potent mitogenic factor for HSCs is platelet-derived
growth factor (PDGF) (7). Multiple signaling pathways are im-
plicated in HSC proliferation. Activation of Ras due to PDGF is
followed by sequential activation of Raf, MEK, and extracellular
signal-regulated kinase (8). Blocking extracellular signal-regu-
lated kinase activity after PDGF stimulation inhibits HSC pro-
liferation (9). Stress-activated kinases also regulate HSC prolif-
eration. Inhibition of JNK in quiescent or culture-activated HSCs
prevented increases in the cell population; however, inhibition of
p38 increased HSC proliferation (10).
The phosphatidylinositol 3-kinase (PI3K)-Akt pathway is
also activated after PDGF treatment of HSCs (11, 12). After
PDGF stimulation PI3K, a heterodimeric protein composed of
an 85-kDa regulatory and 110-kDa catalytic subunit associates
with the PDGF receptor and becomes activated by phosphoryl-
ation. PI3K activation results in the generation of phosphoryl-
ated inositol lipids, essential second messengers for intracellu-
lar signaling (13). Phosphorylated inositol lipid bind to Akt, a
downstream target in the PI3K pathway, and induce its trans-
location to the plasma membrane (14). There Akt becomes
activated by phosphorylation at residues Thr308 and Ser473 by
phosphoinositide-dependent kinase 1 (14, 15). A role of PI3K in
HSC proliferation has been confirmed since inhibition of PI3K
by LY294002 or wortmannin blocks HSC proliferation (12, 16,
17). We have shown that serum or PDGF activates Akt in HSCs
by phosphorylating Ser473. Inhibition of PI3K blocks this activ-
ity. In addition, inhibiting both PI3K and Akt blocks HSC
proliferation and type I collagen synthesis (17).
Another downstream target in the PI3K pathway, via Akt, is
p70 S6 kinase (p70S6K), a ribosomal 70-kDa protein that is
activated by mitogens, growth factors, and several hormones
(18). Furthermore, it is a key regulator of mRNA translation
and protein synthesis and is required for cell cycle progression,
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cell differentiation, and cell growth. Activation of p70S6K occurs
through a complex series of phosphorylation events on several
serine or threonine residues (19). Phosphorylation of these
sites is inhibited by wortmannin, LY294002, rapamycin, and
by amino acid deprivation (20–22). Rapamycin, a lipophilic
bacterial macrolide with immunosuppressive properties, inhib-
its proliferation of yeast and several mammalian cell types
including B and T lymphocytes (8, 23). In HSCs, rapamycin
effectively blocked insulin-like growth factor-induced DNA syn-
thesis (24). Furthermore, rapamycin blocked extracellular ma-
trix deposition in CCl4-induced liver fibrosis (25). Yet, the
molecular mechanism has not been clarified. Here we report
that rapamycin treatment of HSCs inhibits phosphorylation of
p70S6K, leading to an inhibition of type I collagen synthesis,
DNA synthesis, and cell cycle progression.
EXPERIMENTAL PROCEDURES
HSC Isolation and Culture—HSCs were purified from male Sprague-
Dawley retired breeder rats (400 g) as previously described (26).
Isolated HSCs were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum (FBS), standard antibiotics,
and 2 mM L-glutamine in a 95% air, 5% CO2-humidified atmosphere at
37 °C. Growth medium was exchanged every other day. HSCs were
activated by culturing on plastic for 10–14 days. The purity of culture-
activated HSCs was assessed by immunostaining cells using mouse
anti-human smooth muscle -actin (Dako, Carpinteria, CA). All animal
procedures were performed under the guidelines set by the University
of North Carolina Institutional Animal Care and Use Committee and
are in accordance with those set by the National Institutes of Health.
Experimental Protocol—After an activation period of 10–14 days in
culture, HSCs were cultured for 48 h in Dulbecco’s modified Eagle’s
medium without FBS supplementation to synchronize the cells. After
synchronization, cells were treated with 25 M LY294002 (Calbiochem),
10 nM rapamycin (Sigma), or the vehicle Me2SO (Sigma). After 1 h,
HSCs were treated with 10% FBS or 20 ng/ml PDGF-B/B (Roche Ap-
plied Science). In some of the experiments HSCs were stimulated with
10 ng/ml TNF (R&D Systems, Minneapolis, MN) or 5 ng/ml TGF
(R&D Systems).
Western Blot Analysis—Cultured HSCs were washed with phos-
phate-buffered saline, and the cells were lysed using protein sample
buffer (100 mM Tris-HCl, pH 6.8, 200 mM dithiothreitol, 4% SDS, 0.2%
bromphenol blue, 20% glycerol). Protein concentrations were measured
by the Bradford method (Bio-Rad). Protein samples were heated at
95 °C for 5 min, and 20 g was applied to a 10% SDS-polyacrylamide gel
(7.5% SDS-polyacrylamide gels were used for collagen analysis). After
electrophoresis the proteins were electrophoretically transferred onto
nitrocellulose membranes (Schleicher and Schuell). Membranes were
stained with 0.5% Ponceau S to assure equal protein loading. Mem-
branes were blocked for 1 h with 5% powdered nonfat dry milk in TBS-T
(25 mM Tris-HCl, pH 8.0, 144 mM NaCl, 0.1% Tween 20). Afterward,
membranes were incubated with primary and secondary antibodies,
each diluted in TBS-T unless specified otherwise according to Table I.
After incubation with the secondary antibodies, the membranes were
briefly washed twice and then 3 times for 10 min each with TBS-T.
Immunodetected proteins were visualized using the enhanced chemi-
luminescent ECL assay kit (Amersham Biosciences) according to the
manufacturer’s recommended protocol.
Analysis of DNA Synthesis—DNA synthesis was assessed by [3H]thy-
midine incorporation essentially as previously described (17). Culture-
activated HSCs (7–10 days in culture) were seeded at a density of 2 
104 cells/well in 24-well plates in growth medium containing 10% FBS.
After 24 h the medium was changed to 0.2% FBS, and the cells were
incubated for another 24 h to reduce cell proliferation. One hour before
the proliferative trigger cells were treated with 10 nM rapamycin
(Sigma). Afterward, the cells were incubated in medium containing
either 0.2 or 10% FBS for 48 h with 1 Ci/ml [3H]thymidine present
during the last 24 h. At the end of the incubation 10% trichloroacetic
acid was added, and the cells were maintained on ice for 15 min. Cells
were washed twice with cold 10% trichloroacetic acid and solubilized in
0.2 N NaOH, and radioactivity was measured using a scintillation
counter. Experiments were performed in quadruplicate.
RNase Protection Assay—RNase protection assays were performed
as described previously (27). Radiolabeled probes were prepared for rat
1(I) collagen (27) and glyceraldehyde-3-phosphate dehydrogenase
(pTRI-GAPDH-Rat, Ambion; Austin, TX) and mixed with 5 g of total
RNA. Protected fragments were analyzed using standard 6% sequenc-
ing gels. After electrophoresis, bands were visualized by autoradiogra-
TABLE I
HRP, horseradish peroxidase.
Primary antibody Dilutiona/Incubation Secondary antibody Dilutiona/Incubation
Polyclonal rabbit anti-human
phospho-p70S6 kinase (Thr421/
Ser424) (Upstate Biotechnology,
Lake Placid, NY)
1:1500/1 h HRP-conjugated anti-rabbit IgG (Santa Cruz,
Santa Cruz, CA)
1:2500/30 min
Polyclonal rabbit anti-p70S6
kinase (Upstate Biotechnology)
1:1000/1 h HRP-conjugated anti-rabbit IgG (Santa Cruz) 1:1000/30 min
Polyclonal rabbit anti-mouse
phospho-AKT (Ser473) (Cell
Signaling Technology, Beverly,
MA)
1:1000 in 5% bovine
serum albumin
/12 h
HRP-conjugated anti-mouse IgG (Santa
Cruz)
1:2000 in 5% bovine
serum albumin/60
min
Polyclonal rabbit anti-IB (Santa
Cruz)
1:1000/1 h HRP-conjugated anti-rabbit IgG (Santa Cruz) 1:1000/1 h
Monoclonal rabbit anti-rat
collagen Type I (Biodesign,
Saco, ME)
1:1000/1 h HRP-conjugated anti-rabbit IgG (Santa Cruz) 1:2000/1 h
Mouse anti-human smooth muscle
-actin (Dako)
1:1000/1 h HRP-conjugated anti-mouse IgG (Santa
Cruz)
1:1000/30 min
Mouse monoclonal IgG antibody
against anti-human cyclin D1
(Santa Cruz)
1:1000/1 h HRP-conjugated anti-mouse IgG (Santa
Cruz)
1:1000/1 h
Rabbit polyclonal anti-human
cyclin D2 (Santa Cruz)
1:400/10 h HRP-conjugated anti-rabbit IgG (Santa Cruz) 1:400/1 h
Rabbit polyclonal anti-human
cyclin D3 (Santa Cruz)
1:300/1 h HRP-conjugated anti-rabbit IgG (Santa Cruz) 1:1000/1 h
Polyclonal rabbit anti-human
cyclin E (Upstate
Biotechnology)
1:1000/6 h HRP-conjugated anti-rabbit IgG (Santa Cruz) 1:1000/1 h
Rabbit polyclonal anti-human
phospho-Rb Ser780 (Cell
Signaling)
1:1000/2 h HRP-conjugated anti-rabbit IgG (Santa Cruz) 1:1000/1 h
Rabbit polyclonal anti-human
phospho-Rb Ser 795 (Cell
Signaling)
1:1000/2 h HRP-conjugated anti-rabbit IgG (Santa Cruz,
Santa Cruz, CA)
1:1000/1 h
a All antibodies were diluted in 5% nonfat dry milk TBS-Tween solution unless otherwise stated.
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phy, and signals were quantitated by PhosphorImager analysis (Amer-
sham Biosciences).
Fluorescent-activated Cell Sorting (FACS) Analysis—Rat HSCs were
cultured for 10 days then serum-starved for an additional 48 h. Cells
were subsequently treated with 25 M LY294002, 10 nM rapamycin, or
Me2SO as a vehicle control for 1 h. Afterward, 20 ng/ml PDGF-BB was
added, and the cells were incubated for 24 h. For the 48-h time point,
the medium was changed after 24 h, and fresh LY294002, rapamycin,
and PDGF-BB were added. Cells were harvested by scraping, washed in
phosphate-buffered saline, then incubated in 2 mM EDTA in phosphate-
buffered saline for 20 min, washed twice with phosphate-buffered sa-
line, and treated with 100 g/ml RNase for 5 min at room temperature.
Cells were incubated with 50 g/ml propidium iodide at room temper-
ature in the dark for 30 min. Cell cycle state was assessed by flow
cytometry using a FACScan instrument (BD Biosciences).
Type I Collagen Protein Expression—Proteins from culture media
were precipitated with the addition of ammonium sulfate to a final
concentration of 40% at 4 °C. Samples were centrifuged at 10,000  g at
4 °C for 30 min, and the pellet was suspended in 0.5 M acetic acid.
Aliquots of the protein sample were digested with 130 units of pepsin
(Sigma), neutralized with 1.5 M Tris-HCl, pH 8.8, and digested with 8
units of collagenase (Sigma) at room temperature for 30 min. Samples
were applied on a 7.5% polyacrylamide gel, and Western blot analysis
was performed for type I collagen as described above.
Statistical Analysis—Student’s t test was used for determination of
statistical significance as appropriate. Statistical values of p  0.05
were considered to be significant before analysis. Data are presented as
the means  S.E.
RESULTS
LY294002 Treatment Inhibits PDGF-induced p70S6K Phos-
phorylation—To determine whether p70S6K is involved in the
PI3K pathway in HSCs, activated HSCs were serum-starved
for 48 h and then stimulated for 10, 20, 30, and 60 min with 20
ng/ml PDGF in the presence or absence of 25 M LY294002, a
specific PI3K inhibitor. Western blot analysis was performed to
evaluate the effect of LY294002 on phosphorylation of p70S6K.
As shown in Fig. 1, phosphorylated p70S6K is weakly detectable
before stimulation with PDGF. However, stimulation of HSCs
with 20 ng/ml PDGF (Fig. 1) induced phosphorylation of p70S6K
at Thr421/Ser424 after 10, 20, 30, and 60 min of treatment,
whereas LY294002 completely blocked phosphorylation of
p70S6K at all time points. These data demonstrate that PDGF
(and serum, data not shown) stimulate phosphorylation of
p70S6K and that PDGF-induced activation of p70S6K is inhib-
ited by LY treatment. In addition, our data show that p70S6K is
located downstream of PI3K in PDGF-induced cell signaling in
HSCs.
Rapamycin Blocks PDGF-induced Phosphorylation of p70S6K
but Not Phosphorylation of Akt—Rapamycin has been shown to
inhibit activation of p70S6K in several cell types (19, 21). Akt, a
downstream target in the PI3K pathway, is activated by PI3K,
resulting in phosphorylation of residues Thr308 and Ser473
within the activation loop of Akt (14, 15, 28). In HSCs we have
previously shown that serum and PDGF both activate Akt by
phosphorylation of Ser473, which is inhibited by treatment with
LY294002 (17). To assess the effect of rapamycin on Akt and
p70S6K phosphorylation in HSCs, culture-activated HSCs were
serum-starved for 48 h followed by treatment with 10 nM ra-
pamycin for 1 h. Cells were subsequently stimulated with 20
ng/ml PDGF. Western blot analysis demonstrated that 20
ng/ml PDGF resulted in the phosphorylation of Akt (Ser473)
throughout the 1-h time period (Fig. 2A). Expression of phos-
phorylated Akt was highest within 10 min after PDGF treat-
ment and decreased slightly over the experimental period. No
difference was found in the expression of phospho-Akt after
rapamycin treatment compared with Me2SO control-treated
cells. Phosphorylated p70S6K at Thr421/Ser424 was not detected
before PDGF treatment (Fig. 2B); however, after 10 min of
PDGF treatment an induction of p70S6K phosphorylation was
observed that persisted up to 60 min after stimulation. At all
time points, rapamycin completely blocked p70S6K phosphoryl-
ation. These data show that PDGF stimulates phosphorylation
of p70S6K in HSCs and that p70S6K is positioned downstream of
Akt in PDGF-induced signaling in the HSC.
TGF Does Not Change Phosphorylation of p70S6K—TGF is
one of the most important pro-fibrogenic cytokines for the HSC
(2). It has also been shown that TGF inhibits HSC prolifera-
tion (29, 30); however, the mechanism is unknown. Because we
have previously shown that the focal adhesion kinase (FAK)-
PI3K-Akt-signaling pathway transduces proliferative signal-
ing in the HSC, we wanted to determine whether TGF inhib-
its FAK-PI3K-Akt signaling, leading to an inhibition of p70S6K
activation. We previously showed that TGF fails to inhibit
PDGF-induced Akt phosphorylation (17). HSCs were treated
with 5 ng/ml TGF alone 1 h before a 20 ng/ml PDGF stimu-
lation simultaneously with a 20 ng/ml PDGF stimulation or 10
min after a 20 ng/ml PDGF stimulation, and the cells were
harvested and assessed for p70S6K phosphorylation. TGF
alone did not induce p70S6K phosphorylation (Fig. 3, second
FIG. 1. LY204002 inhibits PDGF-BB-induced phosphorylation
of p70S6K. Rat HSCs were cultured for 10–14 days then serum-starved
in medium containing 0% serum for 48 h. HSCs were either left un-
treated as a control, preincubated with Me2SO, or treated with 25 M
LY294002 for 1 h before stimulation 20 ng/ml PDGF for the indicated
time periods. Cellular proteins (20 g) were analyzed by Western blot
analysis under reducing conditions after 0, 10, 20, 30, and 60 min of
stimulation. The blots were probed for phosphorylated p70S6K (Thr421/
Ser424). Equal sample loading was assessed by Ponceau Red staining of
the membrane after protein transfer.
FIG. 2. Rapamycin prevents phos-
phorylation of p70S6K but not the pro-
tein kinase Akt. Rat HSCs were cul-
tured for 10–14 days and then serum-
starved for 48 h. HSCs were either left
untreated as a control, preincubated with
Me2SO, or treated with 10 nM rapamycin
for 1 h before stimulation with 20 ng/ml
PDGF. Cellular proteins (20 g) were
harvested after stimulation periods of 0,
10, 20, 30, and 60 min, separated on a
10% SDS-PAGE, and transferred on a ni-
trocellulose membrane. Western blot
analysis was performed using anti-phos-
pho-Akt (Ser473) (A) and anti-phospho-
p70S6K (Thr421/Ser424) (B) antibodies.
Equal sample loading was assessed by
Ponceau Red staining of the membrane
after protein transfer.
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lane from left); however, as demonstrated above, PDGF stim-
ulation induced p70S6K phosphorylation (Fig. 3, third lane).
The addition of TGF 1 h before (Fig. 3, fourth lane), at the
same time (Fig. 3, fifth lane), or 10 min after stimulation with
PDGF (Fig. 3, sixth lane) did not alter p70S6K phosphorylation.
These data indicate that TGF does not inhibit HSC prolifer-
ation via the p70S6K signaling pathway in HSCs.
TNF Does Not Induce Phosphorylation of p70S6K in HSCs—
TNF has been reported to activate PI3K signaling in several
cell types (31). Therefore, we wanted to evaluate the effect of
TNF on p70S6K activation in activated HSCs. HSCs were
serum-starved in 0% serum for 48 h then treated with 10 ng/ml
TNF for 10, 20, 30, and 60 min or 20 ng/ml PDGF for 10, 20,
and 30 min, which served as a control for p70S6K phosphoryl-
ation. As expected, PDGF lead to phosphorylation of p70S6K at
all time points (Fig. 4, first through third lanes). In contrast,
phosphorylated p70S6K was not detected after TNF stimula-
tion (Fig. 4, fifth through eighth lanes). Degradation of IB
served as a control for TNF activity. IB protein was de-
tected at 0 and 10 min after TNF stimulation; however, after
20 and 30 min following TNF treatment, degradation of IB
was noted. IB expression was again detected after 60 min of
TNF treatment. This transient degradation of IB is a typ-
ical response to TNF treatment previously shown in HSCs
(32). Together, these results demonstrate that TNF does not
stimulate p70S6K activity in activated HSCs.
Inhibiting p70S6K Kinase Does Not Attenuate 1(I) Collagen
mRNA Expression but Does Decrease Type I Collagen Protein
Expression—Because HSCs are the major source of collagen
during hepatic fibrogenesis, we investigated the influence of
p70S6K on 1(I) collagen mRNA and type I collagen protein
levels. We have previously shown that inhibition of PI3K de-
creases 1(I) collagen mRNA and type I collagen protein secre-
tion from culture-activated HSCs (17). HSCs were cultured on
plastic, and after 10 days in culture the cells were treated with
Me2SO or 10 nM rapamycin for up to 72 h, with fresh media and
treatments replaced every 24 h. Inhibiting p70S6K activity with
rapamycin did not significantly attenuate 1(I) collagen mRNA
expression (Fig. 5).
To assess the effects of blocking PI3K or p70S6K activity on
type I collagen production, Western blot analysis was per-
formed for type I collagen from cultured media. Treatment of
the cells with 25 M LY294002 significantly reduced type I
collagen protein levels within 48 and 72 h compared with
control Me2SO-treated cells (Fig. 6A). Treatment of the cells
with 10 nM rapamycin also inhibited extracellular type I colla-
gen protein expression although not to the extent that was
observed in the LY294002-treated cells (Fig. 6A). HSC cellular
extracts were also examined for intracellular type I collagen
protein levels after treatment with Me2SO, 25 M LY294002, or
10 nM rapamycin. LY294002 treatment significantly reduced
type I collagen intracellular protein levels both at days 3 and 7
compared with control values (Fig. 6B). Moreover, rapamycin
similarly blunted collagen I protein expression (Fig. 6C).
To determine whether p70S6K is required for activation of
HSCs in culture, HSCs were cultured and treated with 10 nM
rapamycin or Me2SO as a control. Western blot analysis
showed that there is no significant difference in the level of
-SMA expression between HSCs treated with Me2SO or rapa-
mycin at day 3 or 7, indicating p70S6K is not required for
activation of HSCs (Fig. 6D).
Inhibition of p70S6K Decreases the Relative Proliferation Rate
in HSCs—We have previously shown that inhibition of PI3K or
Akt attenuates HSC proliferation (17). To investigate whether
inhibition of p70S6K pathway would prevent HSC proliferation,
[3H]thymidine incorporation was assessed to measure DNA
synthesis, a classical indicator of cell proliferation, 10–14 days
after isolation. After a 24-h period of serum starvation, DNA
synthesis of HSCs was stimulated using 10% FBS. We have
shown a similar induction of cell proliferation when either
serum or 20 mg/ml PDGF is used as a proliferative stimulus
(data not shown). Before adding the proliferative stimulus,
cells were treated with 10 nM rapamycin for 1 h. After stimu-
lation with 10% serum, the relative proliferation rate was
increased 2.5-fold compared with cells treated with 0.2% serum
(Fig. 7). In contrast, HSCs stimulated with 10% serum and
pretreated with 10 nM rapamycin showed a significant reduc-
tion in the proliferative rate compared with HSCs stimulated
with 10% serum. Cells stimulated with 0.2% serum that were
treated with 10 nM rapamycin exhibited a proliferation rate
that was not significantly different from cells treated with 0.2%
FIG. 3. TGF alone or in combination with PDGF does not
alter phosphorylation of p70S6K. HSCs were cultured for 10–14 days
after isolation, serum-starved for 48 h, then left untreated (first lane),
treated with 5 ng/ml TGF (second lane), or treated with 20 ng/ml
PDGF (third lane), TGF 1 h before PDGF stimulation (fourth lane)
simultaneously with TGF and PDGF (fifth lane), and TGF 10 min
after PDGF stimulation (sixth lane). Cellular proteins (20 g) were
analyzed by Western blot under reducing conditions after 0, 10, 20, 30,
and 60 min of stimulation. The blots were probed against phosphoryl-
ated p70S6K (Thr421/Ser424). Equal sample loading was assessed by
Ponceau Red staining of the membrane after protein transfer.
FIG. 4. TNF does not phosphorylate p70S6K in HSCs. HSCs
were cultured and serum-starved under the same conditions as previ-
ously mentioned. As a control HSCs were treated for 10, 20, and 30 min
with 20 ng/ml PDGF (first through third lanes). HSCs were either left
untreated (fourth lane) or treated with 10 ng/ml TNF for 10, 20, 30 or
60 min (fifth through eighth lanes). Whole cellular proteins (20 g) were
separated on a 10% SDS-PAGE, then transferred to nitrocellulose mem-
branes. Immunoblots were probed with polyclonal anti-phospho-S6K
(Thr421/Ser424). The same blot was stripped and re-probed with poly-
clonal anti-IB.
FIG. 5. Rapamycin does not inhibit 1(I) collagen mRNA ex-
pression in activated rat HSCs. RNase protection assays were per-
formed as described under “Experimental Procedures” with total RNA
extracted from activated HSCs, treated once a day with the Me2SO or
10 nM rapamycin for 24, 48, or 72 h. Expression of 1(I) collagen mRNA
was normalized to expression of -actin for Me2SO (DMSO) vehicle-
treated HSCs. Expression in the presence of rapamycin is shown rela-
tive to that of Me2SO-treated cells. Data represent means  S.E.
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serum alone. Together these data suggest that p70S6K signal-
ing is involved regulating DNA synthesis in HSCs.
Inhibition of PI3K and p70S6K Blocks HSC Proliferation at
the G1-S Checkpoint—Both PI3K and p70
S6K positively influ-
ence cell proliferation. We next wanted to assess where in the
cell cycle LY294002 and rapamycin, inhibitors of PI3K and
p70S6K, respectively, block HSC proliferation. To address this,
activated HSCs were serum-starved 48 h then treated with 25
M LY294002, 10 nM rapamycin, or Me2SO as a control for 1 h.
Afterward, the cells were stimulated to proliferate with 10%
fetal calf serum for 24 and 48 h. Cells were harvested and
analyzed by FACS analysis to determine the percentage of cells
in the S/G2/M phase of the cell cycle (Fig. 8A). Serum stimula-
tion significantly increased the percentage of cells in the
S/G2/M cell cycle phases from 17.0  7.0% to 33.0  4.0% after
24 h. A similar increase was observed after 48 h of serum
stimulation, indicating increased cell proliferation. Me2SO
treatment had no appreciable effect on serum-induced cell cycle
progression (Fig. 8B). However, both LY294002 and rapamycin
significantly blocked cell cycle progression at the G1 to S re-
striction point after both 24 and 48 h of treatment to levels
similar to those observed in untreated cells. These data show
that the PI3K-Akt-p70S6K signaling pathway regulates cell
cycle progression at the G1 to S restriction point in the cell
cycle.
Rapamycin Inhibits Cyclin D1 and D3 and Cyclin E Expres-
sion, Whereas Expression of Cyclin D2, Rb-Ser780, and Rb-
Ser795 Are Not Altered—Proliferation of mammalian cells is
controlled at specific stages in the cell cycle. The G1 to S
transition is generally controlled by the D cyclins and cyclin E
(33). Therefore, to assess whether inhibition of p70S6K by ra-
pamycin reduces expression of cell cycle control proteins, HSCs
were cultured on plastic for 10–14 days, serum-starved for
48 h, then treated with 10 nM rapamycin for 1 h before stimu-
lation with 20 ng/ml PDGF for 6, 12, 18, and 24 h. Western blot
analysis showed that cyclins D1, D2, and D3 were present
before PDGF stimulation and at all time points in cells treated
with Me2SO (Fig. 9). Treatment of the cells with PDGF did not
affect protein levels of the three D cyclins analyzed (Fig. 9). In
contrast, cells treated with rapamycin led to a significant re-
duction in the expression of cyclins D1 and D3 protein levels
throughout the experiment (Fig. 9, A and C). However, no
change in cyclin D2 protein levels were observed between
Me2SO- and rapamycin-treated HSCs at 6, 12, 18, and 24 h
(Fig. 9B). Cyclin E protein levels were not detected in unstimu-
lated cells; however, after PDGF stimulation, cyclin E protein
FIG. 6. LY294002 and rapamycin de-
creases PDGF-induced type I colla-
gen protein expression but does not
affect -SMA expression. A, Western
blot of proteins in the culture media from
HSCs treated for 24, 48, and 72 h with
Me2SO, 25 M LY294002, or 10 nM rapa-
mycin and probed for type I collagen. Cul-
ture media was replaced daily. Western
blot of cellular proteins (20 g/lane)
probed for type I collagen (B and C) or
-SMA (D) from HSCs treated daily with
Me2SO (DMSO) or 25 M LY294002 (B) or
10 nM rapamycin (C and D) for 3 and 7
days. The culture media was changed
daily. Equal sample loading was assessed
by Ponceau Red staining of the membrane
after protein transfer.
FIG. 7. Rapamycin inhibits serum-induced DNA synthesis in
HSCs. HSCs were cultured for 10–14 days and then serum-starved for
48 h. HSCs were preincubated with Me2SO or 10 nM rapamycin for 1 h
and then stimulated with 10% FBS for 24 h in medium containing 1
Ci/ml [3H]thymidine. HSCs maintained in 0.2% serum served as a
control. Experiments were performed in quadruplicate. Data represent
means  S.E. a, p  0.05 compared with HSCs treated with 0.2%
serum; b, p  0.05 compared with HSCs stimulated with 10% serum.
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FIG. 8. LY and rapamycin both inhibit HSC proliferation at the G1-S cell cycle checkpoint. Activated HSCs were serum-starved for 48 h
and then subsequently treated with 25 M LY294002 or 10 nM rapamycin (RAPA) or Me2SO (DMSO) as a vehicle control for 1 h. Cells were
stimulated to proliferate with the addition of 10% fetal calf serum (FBS). After 24 or 48 h, cells were harvested, and FACS analysis was performed.
A, representative FACS scan charts showing the percent of cells in G1 or S/G2/M cell cycle phases. B, a graphical representation of the FACS data
from an average of three independent experiments presented. Error bars represent S.E. a represents statistically significant values compared with
unstimulated cells (0%). b represents statistically significant values compared with cells stimulated with 10% serum.
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expression was induced during the 24-h stimulation period.
Rapamycin treatment resulted in a clear reduction of cyclin E
protein levels at each time point (Fig. 9D). Together, we found
that cyclin D1, D3, and E protein levels were reduced when
HSC proliferation was blocked by rapamycin. In addition, re-
verse transcription-PCR analysis demonstrated that mRNA
levels for cyclins D1 and E were accordingly reduced (data not
shown); however, cyclin D2 protein (Fig. 9B) and mRNA levels
(data not shown) were unaffected.
The retinoblastoma gene (Rb) product regulates cell prolif-
eration by controlling progression through the restriction point
within the G1 phase of the cell cycle (34). Phosphorylation of Rb
late in the G1 phase induces Rb to dissociate from the tran-
scription factor E2F, thereby permitting transcription of S-
phase genes and cell cycle progression (35, 36). Therefore, we
performed Western blot analysis to assess Rb phosphorylation
status in HSCs after PDGF and rapamycin treatment. PDGF
did not increase Rb-Ser780- and Rb-Ser795-phosphorylated pro-
tein levels compared with unstimulated HSCs (Fig. 9, E and F).
Moreover, rapamycin did not affect Rb phosphorylation at
these sites throughout the experimental period. These data
indicate that inhibition of p70S6K activity by rapamycin leads
to a decrease in the expression of cyclins D1, D3, and E,
whereas expression of cyclin D2, and phosphorylation of Rb-
Ser780 and Rb- Ser795 are not changed.
DISCUSSION
After a fibrogenic stimulus the HSC changes from a quiescent
non-proliferating cell to an activated and proliferating cell. The
proliferative response of most cells is mediated by the presence of
mitogenic growth factors such as PDGF. On the cell surface,
PDGF binds to its receptor thereby activating a variety of intra-
cellular pathways, with considerable cross-talk between the sig-
naling pathways. From the cytoplasm these signals are transmit-
ted to the nucleus, inducing genes required for cell cycle
progression, ultimately leading to increased proliferation. Here
we demonstrate that p70S6K is a crucial downstream target in
HSC proliferation and cell cycle control after PDGF stimulation.
The PI3K/Akt pathway is activated after PDGF stimulation
of HSCs (11, 12, 17). A role of PI3K in HSC proliferation is
supported by in vivo studies in rats where CCl4 treatment lead
to autophosphorylation of the PDGF receptor and increased
PI3K activity (12). Furthermore, wortmannin and the more
specific PI3K inhibitor LY294002 blocked mitogenesis in re-
sponse to PDGF, supporting the involvement of this pathway in
HSC proliferation (12, 16). We demonstrated that p70S6K is
positioned downstream of PI3K in HSCs since inhibition of
PI3K by LY294002 prevented PDGF-induced p70S6K phospho-
rylation (Fig. 1). This observation is supported by data in other
cell types, where p70S6K is also positioned downstream of PI3K
and the target of rapamycin (FRAP/mTOR) and is a distinct
signaling pathway of the Ras/mitogen-activated protein kinase
cascade (20). Akt is another key downstream survival factor in
several cell types. Overexpression of a constitutively active
form of Akt stimulates p70S6K and promotes cell proliferation
and survival (37–39). Recently, we were able to show that Akt
becomes activated in HSCs following PDGF stimulation after
phosphorylation of Ser473. Inhibition of PI3K using LY294002
blocked this activity (17). Inhibition of PI3K and Akt activation
also markedly reduced HSC proliferation, 1(I) collagen mRNA
expression, and secretion of type I collagen protein. Transduc-
tion of HSCs with an adenovirus expressing a constitutively
active form of Akt induced HSC proliferation in low serum
conditions, suggesting Akt is positioned downstream of PI3K
and confirming its role in HSC proliferation (17).
To evaluate the role and the position of p70S6K in the PI3K-
Akt signaling pathway, we treated HSCs with rapamycin fol-
lowed by PDGF stimulation. Rapamycin, a bacterial macrolide
with antifungal and immunosuppressant activities, has been
shown to lead to the dephosphorylation and subsequent inac-
tivation of p70S6K (23, 40). Phosphorylation of Thr412 is impor-
tant for p70S6K function in vivo (41). Ser411, Thr421, and Ser424
lie within a Ser-Pro-rich region located within the pseudosub-
strate region (20). Rapamycin, therefore, represents a vali-
dated and adequate tool for blocking p70S6K activity as it has
been used on a regular basis in other cell types for inhibition of
p70S6K (42, 43). We show that rapamycin inhibited PDGF-
induced phosphorylation of p70S6K but not Akt phosphoryla-
tion, suggesting that p70S6K lies downstream of Akt (Fig. 2).
Inhibition of p70S6K phosphorylation by rapamycin did not
influence 1(I) collagen mRNA expression but did reduce both
intracellular and extracellular type I collagen protein expres-
sion, unlike PI3K or Akt, which showed little effect on regula-
tion of 1(I) collagen gene transcription. Thus, collagen gene
expression appears to be more dependent on PI3K activity,
FIG. 9. Rapamycin reduces cyclin D1, D3, E protein levels but
not cyclin D2, Rb-Ser780, or Rb-Ser795 protein levels after PDGF
stimulation. HSCs were isolated and cultured for 10–14 days and then
synchronized by culturing in medium containing 0% serum for 48 h.
HSCs were either left untreated as a control or preincubated with
Me2SO or 10 nM rapamycin for 1 h before stimulation with 20 ng/ml
PDGF. Cellular proteins (20 g) were analyzed by Western blot after 0,
6, 12, 18, and 24 h of stimulation. Immunoblots were probed for cyclin
D1 (A), cyclin D2 (B), cyclin D3 (C), cyclin E (D), RbSer780 (E), RbSer795
(F).
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which suggests that a divergence in PI3K activities is present
in HSCs, one branch leading to collagen expression and the
other continuing through Akt and p70S6K, resulting in a pro-
liferative response. Indeed, our findings demonstrated similar
results with the PI3K inhibitor LY294002, confirming the
downstream position of p70S6K in the PI3K/Akt pathway (Figs.
5 and 6). These results are in accordance with data in other cell
types, where p70S6K stimulation was dependent on PI3K (44–
46). Similar results were obtained in HSCs stimulated by ac-
etaldehyde, which is generated by oxidation of ethanol in vivo
(47). Because ethanol is one of the major causes of liver fibrosis
in patients, the biologic effects of this active ethanol metabolite
are of great importance (48).
One major component of liver fibrosis is the increased pro-
liferation of HSCs. This response is at least partially responsi-
ble for increased expression and deposition of extracellular
matrix proteins (48). The data presented here show that rapa-
mycin is potently able to block HSC proliferation. Inhibition of
PI3K and Akt also blocked HSC proliferation (Fig. 7) (17).
Together, these data suggest that the PI3K-Akt-p70S6K path-
way is crucial in proliferative signaling in HSCs. We previously
demonstrated that inhibition of PI3K activity inhibits 1(I)
collagen gene expression (17). However, in this study we
showed that inhibiting p70S6K activity does not reduce 1(I)
collagen mRNA expression; however, inhibition of p70S6K
blocks intracellular as well as extracellular type I collagen
protein expression. Therefore, it is possible that rapamycin
alters translational efficiency in HSCs, as previously shown in
other cell types (21, 49). The likely mechanisms by which
rapamycin blocks p70S6K activity is either by direct inhibition
of p70S6K phosphorylation in the PI3K pathway or by inhibition
of the mTOR/FRAP-induced phosphorylation (21, 23). Rapamy-
cin represses translation of mRNA subsets including tran-
scripts of the translational apparatus, i.e. ribosomal proteins
and elongation factors required for protein synthesis. Ulti-
mately this results in an impairment of mRNA translation and
reduction of protein levels (18, 21, 44, 50).
As a potent profibrogenic cytokine, TGF is able to stimulate
collagen mRNA and protein synthesis (51, 52). Furthermore,
TGF is anti-proliferative in HSCs (29). Surprisingly, TGF
did not influence the phosphorylation status of p70S6K induced
by PDGF (Fig. 3). Therefore, the anti-proliferative actions of
TGF must be independent of the PI3K pathway, possibly
mediated through Ras, extracellular signal-regulated kinase,
and MEK signaling. After a fibrogenic stimulus, HSCs become
activated and start to express smooth muscle -actin (4). Our
results show that rapamycin treatment did not change -SMA
protein levels, indicating that p70S6K actions are independent
of the stellate cell activation process.
As a mitogen-activated Ser/Thr protein kinase, p70S6K is
required for G1 cell cycle progression and cell growth (20).
p70S6K phosphorylates the S6 protein of the 40 S ribosomal
subunit and is involved in translational control of 5-oligopyri-
midine tract mRNAs (20). It has been shown that rapamycin is
effectively able to block protein synthesis and to arrest cell
cycle progression in the G1 phase by inhibition of the G1/S
transition (18, 53). This inhibition is the consequence of rapa-
mycin effect on cyclin D1 mRNA and protein stability (54). The
various forms of cyclins comprise the regulatory subunits of
kinase complexes, which control cell proliferation at specific
stages in the cell cycle. These kinase complexes mediate phos-
phorylation of Rb during G1 (55, 56). The controlled activation
of the kinase complexes at various intervals of the cell cycle is
regulated by the availability of the cyclins to the catalytic
subunit. Unlike the catalytic subunit, which is expressed con-
tinually, the expression and stability of the regulatory subunit
fluctuates depending on the stage of the cell cycle, thereby
regulating kinase activity. Accumulation evidence suggested
that D-type cyclins play an important role in cell cycle progres-
sion (34, 57). Overexpression of cyclin D1 in rat fibroblasts
caused a more rapid entry into the S phase (58, 59). Moreover,
cyclin D expression is controlled post-transcriptionally via the
PI3K/Akt-dependent pathway (60). For example, cyclin E
works as a cofactor for cyclin-dependent kinase 2 (cdk2) in late
G1 phase (61). Cyclin-cdk complexes play an important role in
cell cycle transition from G1 to S since microinjection of these
complexes induced DNA synthesis in human fibroblasts (62). In
murine HSCs it has been shown that expression of cyclin D1,
D2, and E correlated with proliferation and LY294002 inhib-
ited expression of cyclin D1 (63). We were able to show that
rapamycin treatment lead to a decrease in expression of cyclin
D1, cyclin D3, cyclin E but not cyclin D2 mRNA and protein
levels (Fig. 9). One possible explanation could be that expres-
sion of cyclin D2 is influenced by other kinases and that rapa-
mycin treatment alone is not able to block cyclin D2 expression.
Alternatively, cyclin D2 might not be involved in G1/S transi-
tion in this cell type. The ability of rapamycin to inhibit expres-
sion of cyclin D1, D3, and E correlated with an arrest in the G1
phase of the cell cycle as demonstrated by FACS analysis
(Fig. 8).
As stated above, the tumor suppressor Rb is an important
factor in the cell cycle. Rb controls progression through the late
G1 restriction point and is a major regulator of the G1/S tran-
sition (34). Cell cycle progression is induced by phosphorylation
of Rb at several specific sites by cyclin-dependent kinases and
their regulatory subunits. Phosphorylation of Rb leads to the
dissociation of transcription factors, which induce genes re-
quired for cell cycle progression (35, 36). However, Rb phospho-
rylation at Ser780 and Ser795 was not affected by rapamycin in
HSCs (Figs. 9, E and F). A possible explanation is that Ser780
and Ser795 are not the primary phosphorylation sites involved
in cell cycle arrest. Rb has numerous known phosphorylation
sites and potentially yet undiscovered ones that might be un-
phosphorylated, thereby still preventing cell cycle progression.
Such sites potentially include Ser807/811, Ser249/252, Thr373, and
Ser608. We investigated Rb phosphorylation at Ser795 since the
role of this site is important for regulating cell cycle progression
in other cell types as mitogen-induced phosphorylation of Rb at
this site (64). However, it has also been shown that Ser795 and
the surrounding region is important for E2F binding, but mu-
FIG. 10. Proliferative signaling in hepatic stellate cells. FAK,
focal adhesion kinase; PDK-1, phosphoinositide-dependent kinase 1; JNK,
c-Jun NH2-terminal kinase; ERK, extracellular signal-regulated kinase;
PtdIns(3,4)P2, phosphatidylinositol 3,4,-phosphate; PtdIns(3,4,5)P3, phos-
phatidylinositol 3,4,5-phosphate; ECM, extracellular matrix; D3PPI, D3-
phosphorylated phosphoinositides; PTEN, phosphatase and tensin hom-
olog deleted on chromosome ten; MKK, mitogen-activated protein kinase
kinase.
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tation of Ser795 alone is not sufficient to inhibit E2F binding
(65). Thus, multiple phosphorylation sites seem to regulate
protein binding activity of Rb toward E2F and subsequent cell
proliferation. Finally, in a model of heat-induced G1 arrest, cell
cycle progression was inhibited regardless of Rb phosphoryla-
tion at Ser780/795 (66).
In summary, our results demonstrate that the PI3K-Akt-
p70S6K signaling pathway is important for transmitting
PDGF-induced proliferative signaling in the activated HSC
(Fig. 10). p70S6K is positioned downstream of PI3K and Akt.
p70S6K phosphorylation is required for maximal induction of
cyclin D1, D3, and E, which are required for cell cycle pro-
gression in this cell type. However, phosphorylation sites
Ser780 and Ser795 of Rb are most likely not required for cell
cycle arrest in HSCs and are independent of p70S6K phospho-
rylation. Ultimately, p70S6K might represent a therapeutic
target to inhibit collagen deposition through inhibition of
HSC proliferation during hepatic fibrogenesis.
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